Company intelligence / Profile preview

Rubedo Life Sciences

Sunnyvale, California, United Statesrubedolife.com ↗

Ownership: Private
Employees: ~27
Development stage: Phase 1

Overview

Rubedo is advancing its lead candidate RLS-1496 into Phase 1 studies for chronic atopic dermatitis and chronic psoriasis. The company has developed novel senolytic compounds showing efficacy both in vitro and in vivo, with a focus on selectively targeting senescent cells while preserving healthy cells.

Therapeutic areas: PulmonologyMetabolic DisordersDermatologyOncologyNeurology
Modalities: Small moleculesprodrugs
Industry: Biotech

Drug pipeline

5 assets

RLS-1496

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Rubedo Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rubedo Life Sciences.

Explore the full profile